Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

CEFEPIME

All injection strengths: not a benefit

Other products in the same Health Canada class (J01D) — coverage varies; not interchangeable

  • Ertapenem (Invanz): not a benefit

Apo-Cefepime · DIN 02467496 · 1g · powder for injection, vial

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-19
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Apo-Cefepime · DIN 02467496 Manufacturer: Apotex Inc.; listing date 2018-08-30 Health Canada: Marketed since 2018-05-14 · brand APO-CEFEPIME · ATC J01DE01 CEFEPIME · form Powder for solution · route Intramuscular, Intravenous · ingredients CEFEPIME (CEFEPIME HYDROCHLORIDE) 1 G/VIAL · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95586 · Verify on the e-Formulary ↗ (DIN 02467496)

Source record
DIN 02467496: Apo-Cefepime Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 084000065; group id 129; item number 0217; lccId None; manufacturer id APX Source form: Inj Pd-Vial Pk; strength: 1g Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $31.2700; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02467496 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95586
Interchangeable products
Cefepime for Injection · DIN 02319020 · not recorded Maxipime · DIN 02163632 · not recorded
Shortage status: not checked (no credentials)
Other drugs in the same formulary class (08:40 Miscellaneous Anti-Infectives) and how they are covered

Matched class: 08:40 Miscellaneous Anti-Infectives

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Some products covered without a code (check the product listing): CIPROFLOXACIN, LEVOFLOXACIN, MOXIFLOXACIN HYDROCHLORIDE, NORFLOXACIN, SULFAMETHOXAZOLE & TRIMETHOPRIM, TRIMETHOPRIM 08:40 Miscellaneous Anti-Infectives

ERTAPENEM

· 5 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 1g/Vial · Inj Pd-Vial Pk

CIPROFLOXACIN

· 44 products · Limited Use, codes 533 (1), Listed, not a benefit (3), General benefit (40) · strengths: 10g/100mL, 250mg, 500mg, 750mg · Oral Susp, Tab

LEVOFLOXACIN

· 24 products · Listed, not a benefit (2), General benefit (14), Off-Formulary Interchangeable, not an ODB benefit (8) · strengths: 250mg, 500mg, 750mg · Tab

MOXIFLOXACIN HYDROCHLORIDE

· 12 products · Listed, not a benefit (1), General benefit (11) · strengths: 400mg · Tab

NORFLOXACIN

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 400mg · Tab

SULFAMETHOXAZOLE & TRIMETHOPRIM

· 9 products · Listed, not a benefit (6), General benefit (3) · strengths: 40mg & 8mg/mL, 400mg & 80mg, 800mg & 160mg · O/L, Tab

TRIMETHOPRIM

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 100mg, 200mg · Tab

CIPROFLOXACIN HCL & CIPROFLOXACIN BASE

· 2 products · Listed, not a benefit (1), Limited Use, codes 394 (1) · strengths: 500mg · ER Tab

LINEZOLID

· 6 products · Off-Formulary Interchangeable, not an ODB benefit (2), Listed, not a benefit (1), Limited Use, codes 362, 363, 364 (3) · strengths: 2mg/mL, 600mg · Inj-300mL Pk, Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 08:40
Full class listing Related classes: 08:08 Anthelmintics, 08:12 Antibiotics, 08:14 Antifungals, 08:16 Antitubercular Agents, 08:18 Antivirals, 08:20 Plasmodicides (Antimalarials), 08:24 Sulfonamides, 08:30 Antiprotozoals, 08:32 Trichomonacides, 08:36 Urinary Anti-Infectives Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE Treatment APO-CEFEPIME (cefepime for injection) is indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms: ADULTS Lower respiratory tract infections: Nosocomial and community acquired pneumonia caused by Pseudomonas aeruginosa, Staphylococcus aureus (methicillin-susceptible strains), Streptococcus pneumoniae, Escherichia coli, and Haemophilus influenzae. Acute exacerbations of chronic bronchitis caused by Streptococcus pneumoniae and Haemophilus influenzae. Uncomplicated and complicated urinary tract infections, including pyelonephritis caused by Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, and Proteus mirabills. Due to the nature of the underlying conditions which usually predispose patients to Pseudomonas infections of the lower respiratory and urinary tracts, a good clinical response accompanied by bacterial eradication may not be achieved despite evidence of in vitro sensitivity. Skin and skin structure infections caused by Staphylococcus aureus (methicillin- susceptible strains), Streptococcus pyogenes (Group A streptococci), and Pseudomonas aeruginosa. … https://pdf.hres.ca/dpd_pm/00053918.PDF PM date: not printed or not captured Source product: APO-CEFEPIME; DIN 02467496; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Other review policies

For Apo-Cefepime: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026